How did BRNS manage to reduce expenses while increasing revenue in Q3 2024?

Barinthus Biotherapeutics (BRNS) did not manage to increase revenue in Q3 2024, as evidenced by the earnings per share (EPS) estimates. According to the analysts at HC Wainwright, the company's revenue for Q3 2024 is expected to be ($0.49) per share, which is a decrease from their prior estimate of ($0.38) and a reflection of the challenging financial environment that the company is facing. This indicates that BRNS has been unable to generate more revenue during the quarter, and in fact, has seen a decline in revenue compared to previous estimates.